Osteoporosis Treatment Market By Drug Type (Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), Rank Ligand Inhibitors) - Growth, Share, Opportunities & Competitive Analysis, 2017 – 2025

Osteoporosis is a commonly observed bone disease that weakens bones and further enhances the risk of them breaking. This condition makes bones fragile, thus increasing their susceptibility to fracture. According to the International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds. Thus, with the rising prevalence of osteoporosis, a number of campaigns and programs are conducted by the National Osteoporosis Foundation (NOF), the National Bone Health Alliance, and the Fracture Liaison Service (FLS) to increase awareness about osteoporosis amongst healthcare professionals and individuals, which would further propel the osteoporosis treatment market. With novel drugs in the pipeline, the entry of generics, especially in emerging economies, is anticipated to boost the demand for osteoporosis treatment during the forecast period.

The report titled "Osteoporosis Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall osteoporosis treatment market, along with the market size and estimates for the duration of 2015–2025. The research study in question provides an in-depth examination of multiple market segments based on drug type and geography. The drug types studied for analyzing the overall global osteoporosis treatment market are majorly segmented into bisphosphonates, parathyroid hormone therapy, calcitonin, selective estrogen inhibitor modulator (SERM), and rank ligand inhibitors.

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year. Further cross-sectional analysis in terms of drug and constituent region-level markets is also included in this section.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global osteoporosis treatment market. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the global osteoporosis treatment market's competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global osteoporosis treatment market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the vascular grafts market. The key players profiled in this report are Allergan Plc., Amgen, Inc., Actavis Plc., Eli Lilly and Company, F.Hoffmann La Roche Ltd., GlaxoSmithKline Pharmaceutical Ltd., Merck & Co. AG, Novartis AG, Novo Nordisk A/S, Pfizer, Inc., and Teva Pharmaceuticals Industries Ltd. and others.

Based on the type of drug, the global osteoporosis treatment market is segmented as follows:

  • Bisphosphonates
  • Parathyroid hormone therapy
  • Calcitonin
  • The modulator of Selective Estrogen Inhibitors (SERM)
  • Rank-Ligand Inhibitors

Bisphosphonates are the most commonly prescribed medication for the prevention and treatment of osteoporosis. It occupies the major revenue share, thus dominating the global osteoporosis treatment market due to its wide consumption and high efficacy. High adoption of new drug classes, such as rank ligand inhibitors and parathyroid hormone therapy, further boosts the growth of the osteoporosis treatment market. With the entry of a novel drug class, hurdles such as chronic and generic side effects of the established drugs will be overcome. The entry of generic drugs, especially in developing countries, will help address the clinical need for low-cost medication for the treatment of osteoporosis, which would further exhibit lucrative growth in the forecast period.

For the purpose of this study, the global osteoporosis treatment market is geographically categorized into:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Rest of Asia
  • Latin America
  • Brazil
  • Mexico
  • rest of Latin America
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East and Africa

In 2016, North America dominated the global osteoporosis treatment market, followed by Europe. Currently, in the U.S., osteoporosis and low bone mass are considered major public health threats, affecting around 44 million U.S. women and men aged 50 and older. In Canada, osteoporosis affects approximately 1.4 million individuals, mainly postmenopausal women and the elderly. Primarily due to the aging population, the prevalence of osteoporosis and low bone mass is expected to increase, thus driving the osteoporosis treatment market. Asia Pacific is anticipated to be the fastest-growing regional market in the forecast period of 2017–2025. Even in the most high-risk patients who have already had a fracture, a large portion of the Asian population with osteoporosis remains undiagnosed and untreated. This situation is commonly observed in rural areas. In developing countries such as India and China, where the majority of the population lives in rural areas (60% in China), home care treatments are preferred over surgical treatment in hospitals, even in cases of hip fractures. However, with increased awareness, improved healthcare infrastructure, and a growing population in emerging economies, the osteoporosis treatment market will expand.

Frequently Asked Questions:

The market for Osteoporosis Treatment is expected to reach US$ 16,512.7 Mn in 2025.

The Osteoporosis Treatment market is expected to see significant CAGR growth over the coming years,at 3.9%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Allergan Plc,Amgen Inc.,Actavis Plc.,Eli Lilly and Company,F.Hoffmann La Roche Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Aug 2017
Category:  Pharmaceuticals
Report ID:   58616
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support